x

Posted 03 July, 2023

Aptinyx Inc. appointed new CEO

CEO Change detected for ticker OTC:APTX in a 8-K filed on 03 July, 2023.


  On June 30, 2023, Andrew Kidd, stepped down from his position as interim chief executive officer and principal executive officer, principal financial officer and principal accounting officer of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Aptinyx Inc.
Health Care/Life Sciences • Pharmaceuticals
Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
Market Cap
N/A
View Company Details
Aptinyx Inc. by TradingView
Relevant filing section
Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Director Resignation


On June 30, 2023, Robert Hombach notified Aptinyx, Inc. (the "Company") of his resignation as a member of the Company's board of directors (the "Board"), effective immediately. Mr. Hombach's resignation did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.


Officer Departure


On June 30, 2023, Andrew Kidd, stepped down from his position as interim chief executive officer and principal executive officer, principal financial officer and principal accounting officer of the Company.


Officer Appointment


On June 30, 2023, following Mr. Kidd's resignation, Craig Jalbert was appointed principal executive officer, principal financial officer and principal accounting officer of the Company. As previously disclosed in the Company's Form 8-K filed with the Securities and Exchange Commission on May 5, 2023, Mr. Jalbert will be compensated in the amount of $10,000 per month. Mr. Jalbert will be compensated in the amount of $50,000 per year for a period of three years following the filing of the certificate of dissolution with the Secretary of State of the State of Delaware. There is no arrangement or understanding pursuant to which Mr. Jalbert was appointed to be an officer of the Company. There are no family relationships between Mr. Jalbert and any director or executive officer of the Company, and Mr. Jalbert has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.